KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Equity Income: 2009-2024

Historic Equity Income for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $1.0 million.

  • Teva Pharmaceutical Industries' Equity Income fell 33.33% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year increase of 175.00%. This contributed to the annual value of $1.0 million for FY2024, which is 50.00% down from last year.
  • According to the latest figures from FY2024, Teva Pharmaceutical Industries' Equity Income is $1.0 million, which was down 50.00% from $2.0 million recorded in FY2023.
  • In the past 5 years, Teva Pharmaceutical Industries' Equity Income registered a high of $138.0 million during FY2020, and its lowest value of $1.0 million during FY2024.
  • In the last 3 years, Teva Pharmaceutical Industries' Equity Income had a median value of $2.0 million in 2023 and averaged $8.0 million.
  • Its Equity Income has fluctuated over the past 5 years, first spiked by 1,161.54% in 2020, then crashed by 93.48% in 2021.
  • Yearly analysis of 5 years shows Teva Pharmaceutical Industries' Equity Income stood at $138.0 million in 2020, then tumbled by 93.48% to $9.0 million in 2021, then spiked by 133.33% to $21.0 million in 2022, then plummeted by 90.48% to $2.0 million in 2023, then tumbled by 50.00% to $1.0 million in 2024.